Skip to content

GLP-1 weight loss calculator

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

Unit

Runs in your browser. What you enter stays on your device.

How this works

The calculator multiplies your starting weight by the average share of body weight lost in the weight-management trial printed on each FDA label. It doesn't predict your result. It shows what the average person in the trial would have lost, starting at your weight.

Both trials enrolled adults without diabetes who had obesity, or overweight plus a weight-related health condition. Everyone took the medicine alongside a reduced-calorie diet and increased physical activity.

Averages hide a wide spread. Some people in each trial lost much more than the average and some lost much less.

Where these numbers come from

Average change in body weight in the FDA label trials
Medicine and doseAverage lossPlaceboWeeks
Semaglutide 2.4 mg (Wegovy)14.9%2.4%68
Tirzepatide 5 mg (Zepbound)15.0%3.1%72
Tirzepatide 10 mg (Zepbound)19.5%3.1%72
Tirzepatide 15 mg (Zepbound)20.9%3.1%72

Frequently asked questions

How much weight do people lose on semaglutide?

In the trial on the Wegovy label in adults without diabetes, people taking semaglutide 2.4 mg once a week lost an average of 14.9% of their body weight over 68 weeks, alongside diet and physical activity. The placebo group lost 2.4%.

Source

How much weight do people lose on tirzepatide?

In the trial on the Zepbound label in adults without diabetes, the average loss over 72 weeks was 15.0% of body weight on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, alongside diet and physical activity. The placebo group lost 3.1%.

Source

Will I lose that much?

Maybe more, maybe less. These are trial averages and individual results ranged widely. The dose you reach, side effects, diet, activity and how long you stay on the medicine all change the result. Your prescriber can tell you what is realistic for you.

Source

Do people with type 2 diabetes lose the same amount?

Less on average. In the Zepbound label trial in adults with type 2 diabetes, the average loss at 72 weeks was 12.8% on 10 mg and 14.7% on 15 mg, compared with 19.5% and 20.9% in the trial in adults without diabetes.

Source

Sources (2)

  1. 1.
    Wegovy prescribing information: clinical studies
    “After 68 weeks, treatment with WEGOVY injection resulted in a statistically significant reduction in body weight compared with placebo. Greater proportions of patients treated with WEGOVY injection achieved 5%, 10% and 15% weight loss than those treated with placebo as shown in Table 8.”
  2. 2.
    Zepbound prescribing information: clinical studies
    “Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight. % Change from baseline: Study 1 Placebo N = 643: -3.1; Study 1 ZEPBOUND 5 mg N = 630: -15.0; Study 1 ZEPBOUND 10 mg N = 636: -19.5; Study 1 ZEPBOUND 15 mg N = 630: -20.9; Study 2 Placebo N = 315: -3.2; Study 2 ZEPBOUND 10 mg N = 312: -12.8; Study 2 ZEPBOUND 15 mg N = 311: -14.7”